One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Focus on vascular biology: new therapeutic targets in atherosclerosis, aortic dissection, and peripheral artery disease
Filippo Crea
doi : 10.1093/eurheartj/ehae004
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Pages 239–242
Creation of next generation of diverse cardiovascular physician–scientists from developing countries: insights from Research Council of Pakistan
Muhammad Shahzeb Khan 1*, Kaneez Fatima2, and Javed Butler 3,4
doi : 10.1093/eurheartj/ehad493
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Pages 243–246
Exacerbating the burden of cardiovascular disease: how can we address cardiopulmonary risk in individuals with chronic obstructive pulmonary disease?
Dinesh Shrikrishna 1*, Clare J. Taylor2, Carol Stonham3,4, and Chris P. Gale
doi : 10.1093/eurheartj/ehad669
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Pages 247–249
Unspoken science: exploring the significance of body language in science and academia
Mansi Patil 1*, Vishal Patil 1, and Unisha Katre
doi : 10.1093/eurheartj/ehad598
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Pages 250–252,
Routine use of extracorporeal life support in cardiogenic shock after acute myocardial infarction: the jury is still out
Daniela Pedicino 1* and Rocco Vergallo
doi : 10.1093/eurheartj/ehad760
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Pages 253–254
Critical limb-threatening ischaemia and microvascular transformation: clinical implications
Santeri Tarvainen1,2†, Galina Wirth1,2†, Greta Juusola1,2, Olli Hautero3,4, Kari Kalliokoski3,5,6,7, Tanja Sj?ros3,5,6,7, Veikko Nikulainen3, Jouni Taavitsainen1,2, Jarkko Hyt?nen1,2, Crister Frimodig1, Krista Happonen1, Tuomas Selander8, Tomi Laitinen9, Harri H. Hakovirta3,6,10, Juhani Knuuti 3,5,6,7, Nihay Laham-Karam2, Juha Hartikainen 1, Kimmo M?kinen1, Seppo Yl?-Herttuala 1,2, and Petra Korpisalo
doi : 10.1093/eurheartj/ehad562
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Pages 255–264
A conundrum of arterialized capillaries and vascular dilation in chronic limb-threatening ischaemia
Vijay C. Ganta1, W. Schuyler Jones2, and Brian H. Annex
doi : 10.1093/eurheartj/ehad826
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Pages 265–267
Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways
Yehong Li1†, Mengze Zhou1†, Huanqiu Li2†, Chen Dai3†, Li Yin1, Chunxiao Liu1, Yuxin Li1, Enming Zhang1, Xinli Dong1, Hui Ji1, and Qinghua Hu
doi : 10.1093/eurheartj/ehad796
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Pages 268–283
Macrophage-derived foam cells play a causal role during the pathogenesis of atherosclerosis. P2Y6 receptor (P2Y6R) highly expressed has been considered as a disease-causing factor in atherogenesis, but the detailed mechanism remains unknown.
Drugging the foam cell: identifying P2Y6 antagonists that limit atherosclerosis
Katey J. Rayner
doi : 10.1093/eurheartj/ehad846
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Pages 284–286
On target inhibition of vascular smooth muscle cell phenotypic transition underpins TNF–OXPHOS–AP-1 as a promising avenue for anti-remodelling interventions in aortic dissection and rupture
Kapka Miteva
doi : 10.1093/eurheartj/ehad679
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Pages 306–308
Overnight exposure to high altitude in pulmonary hypertension: adverse events and effect of oxygen therapy
Simon R. Schneider , Julian Müller , Meret Bauer, Laura Mayer, Lea Lü?nd, Tanja Ulrich, Michael Furian , Aglaia Forrer, Arcangelo Carta , Esther I. Schwarz , Konrad E. Bloch , Mona Lichtblau , and Silvia Ulrich
doi : 10.1093/eurheartj/ehad789
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Pages 309–311
Immunology and atherosclerosis: is there an individual ID which defines our susceptibility?
I?igo Lozano 1*, Ana Su?rez2,3, and Javier Rodriguez-Carrio2
doi : 10.1093/eurheartj/ehad700
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Page 312
Inflammation contributes to the pathogenic effects of subclinical atherosclerosis
F?tima S?nchez-Cabo 1,2, Valent?n Fuster 1,3*, and Enrique Lara-Pezzi
doi : 10.1093/eurheartj/ehad701
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Page 313
Percutaneous closure of infantile postoperative left ventricular pseudoaneurysm exclusively under transthoracic echocardiography guidance
Huai-Xue Mi1,2, Peng-Peng Wu3, and Li Hongxin
doi : 10.1093/eurheartj/ehad606
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Page 314
Optical coherence tomographic patterns of restenosis in patients treated with directional coronary atherectomy and drug-coated balloon therapy
Akihiro Nakajima *, Masaaki Okutsu, and Sunao Nakamura
doi : 10.1093/eurheartj/ehad694
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Page 315
Correction to: HFrEF phenotyping in real life
doi : 10.1093/eurheartj/ehad839
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Page 283
Correction to: Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
doi : 10.1093/eurheartj/ehad854
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Page 286
Correction to: Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry
doi : 10.1093/eurheartj/ehad855
European Heart Journal, Volume 45, Issue 4, 21 January 2024, Page 308
